Comorbidities in patients with Familial Mediterranean Fever

Results The mean age was 27,5±16 (1-86) years. Our hospital mean follow-up period was 48,5±48 (1-352) months. 1343 patients (67,2%) had no comorbidities. 655 patients (32.8%) had comorbidities. Comorbidities were as follow: Appendectomy 30 (4,6%), cholecystectomy 20 (3,1%), acute rheumatic fever (2,4%), ankylosing spondylitis 155 (23,7%), juvenile idiopathic arthritis 31 (4,6%), rheumatoid arthritis 10 (1,5%), renal amyloidosis 54 (8,2%), intestinal amyloidosis 4 (0,6%), chronic renal failure 33 (5%), Behçet’s disease 1 (0,2%), Henoch-Schönlein purpura 25 (3,8%), osteoporosis 77 (11,8%), celiac disease 5 (0,8%), inflammatory bowel disease 16 (2,4%), hepatosplenomegaly 33 (5%), hepatosteatosis 20 (3,1%), hypertension 53 (8,1%), polyarteritis nodosa 9 (1,4%), epilepsy 7 (1,1%), multiple sclerosis 5 (0,8%), PFAPA 4 (0,6%), uveitis 1 (0,2%), asthma 6 (0,9%), IgA deficiency 4 (0,6%), thalassemia trait 8 (1,2 %), thalassemi major 1 (0,2 %), systemic lupus erythematosus 5 (0,8 %), sjogren syndrome 2 (0,4%), autoimmune hepatitis 2 (0,4%), autoimmune hemolytic anemia 2 (0,4%) ... Homozygous M694V frequency in patients with comorbidities was 42,7% while it was 34,4% in those without comorbidities. M694V/M694V mutation in patients with comorbidities was significantly more frequent.